World's Best Scientists 2026 revealed!
Catherine Thieblemont

Catherine Thieblemont

D-Index & Metrics

Medicine

D-Index
103
Citations
42093
World Ranking
7318
National Ranking
225

Catherine Thieblemont publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Catherine Thieblemont sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 715 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Catherine Thieblemont D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Catherine Thieblemont sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Catherine Thieblemont is a researcher affiliated with Université Paris Cité in France. Their primary field of study is Medicine, with a strong focus on subfields such as Pathology and Forensic Medicine, Oncology, Genetics, Immunology, and Molecular Biology.

Their research topics include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Acute Lymphoblastic Leukemia research
  • Monoclonal and Polyclonal Antibodies Research

They have contributed to several recent papers, including:

  • Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial, 2021, Nature Medicine
  • Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial, 2022, Journal of Clinical Oncology
  • Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, 2020, Blood Advances
  • Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA), 2021, Annals of Oncology
  • A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma, 2022, Nature Medicine

The researcher collaborates frequently with other scientists in their field. Notable co-authors include:

  • Olivier Casasnovas
  • Franck Morschhauser
  • Emmanuel Bachy
  • Steven Le Gouill
  • Roch Houot

Their publications have appeared in several prominent journals, notably:

  • Blood
  • Hematological Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere

Best Publications

  • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

    Bertrand Coiffier;Catherine Thieblemont;Eric Van Den Neste;Gérard Lepeu

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

    Philippe Colombat;Gilles Salles;Nicole Brousse;Pitahey Eftekhari

  • Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed

    Catherine Thieblemont;Françoise Berger;Charles Dumontet;Isabelle Moullet

  • Treatment of Older Patients with Mantle-Cell Lymphoma

    H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  • Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

    Frédéric Peyrade;Fabrice Jardin;Catherine Thieblemont;Antoine Thyss

  • Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

    E. Zucca;A. Conconi;T.I. Mughal;A.H. Sarris

  • Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.

    Catherine Thieblemont;Yves Bastion;Francoise Berger;Claire Rieux

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

    Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri

  • Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

    Olivier Hermine;Olivier Hermine;Eva Hoster;Jan Walewski;André Bosly

  • Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

    Arnaud Jaccard;Nathalie Gachard;Benoit Marin;Sylvie Rogez

  • Primary thyroid lymphoma is a heterogeneous disease.

    C. Thieblemont;A. Mayer;C. Dumontet;Y. Barbier

  • Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults

    O. Hequet;Q.H. Le;I. Moullet;E. Pauli

  • Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

    Sandy Amorim;Anastasios Stathis;Mary Gleeson;Sunil Iyengar

  • Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

    Steven Le Gouill;Catherine Thieblemont;Lucie Oberic;Anne Moreau

  • The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

    Catherine Thieblemont;Josette Briere;Nicolas Mounier;Hans-Ullrich Voelker

  • Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients

    Françoise Berger;Pascale Felman;Catherine Thieblemont;Thierry Pradier

  • ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

    M. Dreyling;C. Thieblemont;A. Gallamini;L. Arcaini

  • Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

    Richard Delarue;Hervé Tilly;Nicolas Mounier;Tony Petrella

Frequent Co-Authors

Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Hervé Tilly
Hervé Tilly University of Rouen
Bertrand Coiffier
Bertrand Coiffier Centre Hospitalier Lyon Sud
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Philippe Gaulard
Philippe Gaulard Université Paris Cité
Emanuele Zucca
Emanuele Zucca Universita della Svizzera Italiana
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA can open doors to diverse healthcare roles beyond traditional medical school pathways. Many students choose to boost their credentials or shift specialties through flexible online degrees. For those seeking leadership positions in hospitals or clinics, enrolling in a healthcare administration accelerated degree is one of the most efficient routes to advancement.

Nurses wanting to expand their scope of practice may consider an rn to np bridge program. These programs allow registered nurses to become nurse practitioners with a streamlined curriculum. Additionally, if you’re interested in dietary health and preventative care, earning the best online nutrition degree can lead to careers in nutrition counseling, public health, and wellness coaching.

Aspiring healthcare executives should also explore accredited mha programs online, as these degrees can open up senior roles in healthcare management. Exploring these alternative online degrees allows prospective students to tailor their education to their career goals while enjoying the flexibility of remote learning.

Best Scientists Citing Catherine Thieblemont

Trending Scientists

Recently Published Articles